Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Maves vs Ondra Health

Two GLP-1 desks, one scoreboard. We put Maves and Ondra Health head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 81 · Grade C

Maves

Visit Maves Full brief →
vs
Higher Brief ScoreNo. 14 · Grade B+

Ondra Health

Visit Ondra Health Full brief →

The verdict

Ondra Health takes this head-to-head.

Ondra Health scores 87 to 75 on our six-factor Brief Score — A rare combination of a rock-bottom $93 semaglutide, brand-name access, LegitScript certification and all-50-state reach.

That doesn't make Maves a bad call — it's best for readers who want $99 first-month semaglutide with men's-health and body-optimization framing. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
48
88
Supply Reliability
79
86
Transparency
88
88
Access Breadth
86
90
Clinical Oversight
75
88
Track Record
87
82
MavesBrief Score 75 · 87Ondra Health

Price, coverage & the tracker

MavesOndra Health
Brief Score75/100 (C)87/100 (B+)
SemaglutideFrom $99/mo (starting dose, first-month rate, compounded)$93/mo
TirzepatideNot disclosed$166/mo
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
On the trackerNewnew to the tracker, no prior readingStableprice stable

Maves: New to the tracker on 1 August 2026. The published line reads From $99/mo (starting dose, first-month rate, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Ondra Health: $93 sema / $166 tirz — the lowest accredited nationwide line we track; brand access + LegitScript.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.